SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is gaining significant community traction as investors anticipate major exchange listings and positive momentum from Ethereum's evolving technical landscape. The community is actively discussing the platform's potential for cross-chain automation and is focused on holding through price volatility as they wait for increased market exposure.

A2Z Cust2Mate Solutions Corp. is a technology company, which engages in the development and commercialization of retail smart cart solutions for large grocery stores and supermarkets. It operates through the Smart Carts and Precision Metal Parts segments. The Smart Carts segment offers retail automation solutions. Its platform enables seamless in-cart scanning and payment, allowing shoppers to bypass checkout lines while receiving real-time customized offers and product recommendations. The Precision Metal Parts segment includes the manufacturing and sale of precision metal parts. The company was founded by Joseph Bentsur on January 15, 2018 and is headquartered in Vancouver, Canada.

A2Z Cust2Mate Solutions Corp.

A2Z Smart Technologies Corp.

A2Z Smart Technologies is experiencing heightened investor scrutiny following a volatile earnings report that revealed a growing backlog of orders alongside revised financial results. While the community remains divided over the company's ability to scale smart cart deployments and manage long-term profitability, active discussions are focused on the impact of newly secured non-dilutive financing and the potential for retail media revenue to offset operational losses.

The Real FartCoin as suggested by Truth Terminal, following the "FartCoin Launch Strategy". Full FartCoin Ecosystem with a major focus on Planting Trees across the world.  FartNFTs,FartDAO,FartSwap and many other applications are part of our movement. With the also correct Token Mechanics such as the correct Ticker, Supply, Blockchain and Purpose of the token.  Community ran and funded, with great intentions to follow up with the full "lore" of the FartCoin!

FartCoin

FartCoin is trending as part of the broader meme coin market, with active community debate over whether it serves as a legitimate speculative asset or simply a humorous example of crypto volatility. Investors are closely monitoring its technical price levels and volume trends while comparing it to other established meme projects.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant retail attention as community members rally behind its AI-powered infrastructure and ongoing development, with many investors actively accumulating the token on dips. The discussion is heavily centered on its potential for long-term utility within the Base ecosystem and high-conviction sentiment regarding its growth trajectory as an AI-native DeFi project.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

DEGEN is trending as the community speculates on upcoming updates for the project's social-fi app and potential new exchange listings. Traders are closely watching key technical levels and bullish chart patterns while discussing the potential for a recovery following recent volume surges.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph (GRT) is attracting significant community attention as investors position themselves for an anticipated altcoin rally, driven by its status as essential decentralized data infrastructure for Web3 and AI applications. While some users express frustration over past price performance, many are actively accumulating tokens, citing recent technical developments and high-profile integrations as indicators of long-term utility.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF (NASA) is generating significant community buzz as a targeted vehicle for space infrastructure exposure, particularly due to its inclusion of private SpaceX shares. Traders are actively debating its potential as a momentum play, comparing it to other space-themed assets while monitoring its ability to capture upside from the broader aerospace sector and anticipated industry catalysts.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Community sentiment for XRP remains heavily influenced by the anticipated passage of the CLARITY Act, which investors believe will provide regulatory certainty and facilitate broader institutional integration for the token. Discussions are currently polarized between bulls who are actively accumulating on dips in expectation of a major price rally and skeptics who remain cautious due to historical price volatility and market structure concerns.

Monero

Monero is experiencing significant community attention as investors weigh its role as a premier privacy asset amidst a broader resurgence in the privacy coin sector. Discussions are heavily focused on its potential as a hedge against tightening financial surveillance and the evolving risks posed by emerging quantum computing threats.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is trending as the community rallies around strong momentum and speculation regarding potential major exchange listings. Investors are actively debating the token's long-term utility versus market manipulation, with many choosing to accumulate during price swings while aiming for significant future gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...

<ul class="summary-bullets"><li>The data were presented at the American Urological Association (AUA) 2026 Annual Meeting.</li><li>Candel plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026 for the drug.</li><li>If approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in more than 20 years, the company said.</li></ul> Shares of Candel Therapeutics Inc. (CADL) rose 3% in after-hours trading on Friday following the release of extended follow-up data from its pivotal late-stage trial of CAN-2409 in intermediate- to high-risk localized prostate cancer.The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo in the intention-to-treat population. In the intermediate-risk subgroup — which made up 85% of the 745-patient trial — the benefit was even stronger, with a 41% reduction in risk of recurrence, along with notable improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, the firm said.The data, which reinforces the potential of the drug to reduce the risk of tumor recurrence, were presented at the American Urological Association (AUA) 2026 Annual Meeting.<h2 class="st-heading-2">Plan Ahead</h2>Candel plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026 for the drug. If approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in more than 20 years, the company said.<h2 class="st-heading-2">What Did Phase 3 Results Show?</h2>In December 2024, Candel reported positive late-stage results for CAN-2409. The study met its primary endpoint, showing that patients who received the drug along with standard treatment stayed disease-free longer than those on standard care alone.The drug has already received Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration.<h2 class="st-heading-2">How Did CADL Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has risen 72% over the past 12 months. &nbsp;&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dal-m-amzn-v-unh-in-focus-as-berkshire-rejigs-portfolio/cZXmfX1Rekg">DAL, M, AMZN, V, And UNH Stocks In Focus As Berkshire Rejigs Portfolio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data  

The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo. 

Equity

<ul class="summary-bullets"><li>Candel is set to submit a Biologics License Application to the U.S. Food and Drug Administration by the fourth quarter of 2026.</li><li>The Phase 3 trial, which met its primary endpoint, included 745 patients.</li><li>The company also expects to present additional biomarker data by the third quarter of 2026.</li></ul>Shares of Candel Therapeutics (CADL) climbed 3% higher in pre-market trading on Friday, lifted by growing investor optimism ahead of a closely watched presentation of pivotal follow-up data for its prostate cancer therapy at the American Urological Association (AUA) 2026 Annual Meeting Plenary Program.On Thursday, the biotech firm posted a first-quarter (Q1) loss of $0.14 per share, compared to consensus estimates of a loss of $0.33 per share, according to Fiscal.ai data.<h2 class="st-heading-2">All Eyes On CADL’s Phase 3 Follow-Up Data</h2>Candel is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene (CAN-2409) in patients with localized, intermediate- to high-risk prostate cancer, and also announced plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the treatment by the fourth quarter of 2026.A BLA is a formal request to allow for the marketing and sales of a therapy in the United States.In the third quarter of 2026, the company expects to present additional biomarker data. The drug has already been granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations by the U.S. Food and Drug Administration (FDA).<h2 class="st-heading-2">What Did Phase 3 Results Show?</h2>In December 2024, Candel reported positive Phase 3 results for its CAN-2409 therapy. The study met its primary endpoint, showing that patients who received the drug along with standard treatment stayed disease-free longer than those on standard care alone.The trial was randomized, double-blind, placebo-controlled, and included 745 patients. The goal was to improve disease-free survival in patients with intermediate- to high-risk localized prostate cancer.<h2 class="st-heading-2">Retail’s Take On CADL’s Presentation</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CADL">CADL</a> on Stocktwits remained in the ‘bullish’ zone, while message volumes on the platform surged more than 130% over a 24-hour period.One user expects the readout to be “significant,” as it could show a lower hazard ratio and potentially speed up the drug’s approval process.<stembedurl>https://stocktwits.com/drizz/message/653381214</stembedurl>Another user said that regardless of Friday’s outcome, the company’s market capitalization could more than double by the time Candel submits its BLA, potentially paving the way for a future acquisition.<stembedurl>https://stocktwits.com/drizz/message/653477842</stembedurl>CADL shares have gained around 50% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of stock market chart on a glowing particle world map. BRUN shares rallied 38% this week. (Representative Image: Getty Images)

CADL Retail Bulls See Buyout Potential As Key Cancer Data Catalyst Approaches

Candel Therapeutics is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene in patients with localized, intermediate- to high-risk prostate cancer

CADL Stock Is Surging Again – And Retail Traders Are Watching Friday’s Cancer Data Closely 

<ul class="summary-bullets"><li>The company posted a loss of $0.14 per share, compared to consensus estimates of a loss of $0.33 per share, according to Fiscal.ai data.</li><li>Candel will present its follow-up data at the American Urological Association 2026 annual meeting plenary program on Friday.</li><li>The biotech firm is set to begin a Phase 3 trial for lung cancer treatment in June.</li></ul>Candel Therapeutics (CADL) was in the spotlight on Thursday as investors turned their attention away from the company’s first-quarter earnings toward a highly anticipated follow-up data readout from its pivotal Phase 3 prostate cancer trial.Candel will present the data at the American Urological Association (AUA) 2026 annual meeting plenary program on Friday.<a href="https://stocktwits.com/symbol/CADL">CADL shares</a> were trading around 2% lower at the time of writing.<h2 class="st-heading-2">CADL’s Prostate Cancer Therapy In Focus</h2>In December 2024, Candel announced positive Phase 3 trial results for its CAN-2409 cancer therapy in patients with localized prostate cancer. The study met its primary goal, showing that patients who received CAN-2409 in addition to standard treatment remained disease-free longer than those who received standard treatment alone.The drug has already received Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration (FDA), and Candel now plans to complete manufacturing process validation in the second quarter to support a planned Biologics License Application (BLA) submission in Q4 2026.<h2 class="st-heading-2">CADL To Begin Phase 3 Trial For Lung Cancer Treatment In June</h2>Candel recently reported updated long-term data from a Phase 2 trial studying CAN-2409 in advanced non-small cell lung cancer (NSCLC) patients who had not responded well to prior immunotherapy treatment.Half of the 46 patients in the study survived for more than 24 months despite having difficult-to-treat disease and poor prognostic factors. Median overall survival ranged from 21.5 to 25.4 months across different patient groups. The company plans to begin a Phase 3 trial in June 2026.Separately, the company posted a loss of $0.14 per share, compared to consensus estimates of a loss of $0.33 per share, according to Fiscal.ai data.<h2 class="st-heading-2">CADL Bulls Bet On Positive Data</h2>Retail sentiment trended in the ‘bullish’ territory on Stocktwits, while message volumes remained ‘high’ over a 24-hour period.One user said if the follow-up data readout is positive, the stock could run past $12. It is currently trading at around $9.<stembedurl>https://stocktwits.com/haha1978/message/653346180</stembedurl>Another user expects Friday to be “epic” for the company.<stembedurl>https://stocktwits.com/drizz/message/653351186</stembedurl>The stock has gained around 47% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/crmd-stock-surge-q1-results-defencath-sales/cZX1AAmRe1t">CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow 

Candel Therapeutics generated investor buzz ahead of a key prostate cancer data readout, while its first-quarter loss came narrower than consensus estimates.

Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High  - Here's What Happened

Candel Therapeutics (NASDAQ:CADL) Hits New 52-Week High - What's Next...

Candel Therapeutics (CADL) to Release Earnings on Tuesday

Candel Therapeutics (NASDAQ:CADL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-candel-therapeutics-inc-stock...

Candel Therapeutics (NASDAQ:CADL) Stock Price Up 6.1% - Should You Buy?

Candel Therapeutics (NASDAQ:CADL) Trading 6.1% Higher - Here's Why...

UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline

(RTTNews) - United Community Banks, Inc. (UCB),on Sunday agreed to buy Candel Therapeutics, Inc. (CADL) for up to $2.2 billion, aiming to strengthen its pipeline of treatments for immune-related diseases...

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.read more...

Candel Therapeutics (NASDAQ:CADL) Sees Large Volume Increase - Time to Buy?

Candel Therapeutics (NASDAQ:CADL) Sees Unusually-High Trading Volume - Should You Buy...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Experts and investors are buzzing about the therapeutic potential, comparing its impact and adoption path to the legendary cancer treatment Keytruda.

With a high-conviction clinical signal and robust insider backing, market participants are aggressively positioning for a potential multibillion-dollar acquisition.

Bulls are doubling down, labeling recent price dips as intentional 'shake outs' while highlighting a very tight float that could trap over-leveraged shorts.

Recent Phase 3 data presentations at AUA revealed significant improvements in recurrence-free survival, cementing the therapy as a potential new standard of care.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.23	--	--	N/A
Q1 '26	-$0.30	-$0.14	52.68%	BEAT
Q4 '25	-$0.24	-$0.54	-120.94%	MISSED
Q3 '25	-$0.19	-$0.21	-13.40%	MISSED
Q2 '25	-$0.16	-$0.09	45.02%	BEAT

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest CADL News

CADLCandel Therapeutics Inc